drugset

drugset / Trial / NCT00081601

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601 ↗

Phase 2 Completed 30 enrolled Cephalon

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.

Timeline

Start: 2004-03
Primary completion: 2005-05
Completion: 2005-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	lestaurtinib	Small molecule	—	Oral

Indications